Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Blood Advances|May 16, 2019
Clinicopathologic and genetic characterization of nonacute <i>NPM1</i>-mutated myeloid neoplasmsSanjay S Patel, Caleb Ho, Ryan N Ptashkin, et al.
American Journal of Hematology|May 29, 2015
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosisCharles Herbaux, Nicolas Duployez, Catherine Badens, et al.
Blood Advances|February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialShai Shimony, H Moses Murdock, Julia H Keating, et al.
Transfusion|November 24, 2016
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesAlexander B Pine, Eun-Ju Lee, Mikkael Sekeres, et al.
Cancer|June 27, 2025
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment ConsortiumMichael Boyiadzis, Andrew H Wei, Bruno Paiva, et al.
Blood|April 30, 2011
Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemiaMélanie Bonnet, Marie Loosveld, Bertrand Montpellier, et al.
The Lancet. Haematology|July 22, 2024
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, et al.
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
In Vivo (Athens, Greece)|June 23, 2022
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AMLDaniel H Albert, Neal C Goodwin, Angela M Davies, et al.
Lancet (London, England)|June 13, 2023
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trialUwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Blood Advances|May 16, 2019
Clinicopathologic and genetic characterization of nonacute <i>NPM1</i>-mutated myeloid neoplasmsSanjay S Patel, Caleb Ho, Ryan N Ptashkin, et al.
American Journal of Hematology|May 29, 2015
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosisCharles Herbaux, Nicolas Duployez, Catherine Badens, et al.
Blood Advances|February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialShai Shimony, H Moses Murdock, Julia H Keating, et al.
Transfusion|November 24, 2016
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesAlexander B Pine, Eun-Ju Lee, Mikkael Sekeres, et al.
Cancer|June 27, 2025
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment ConsortiumMichael Boyiadzis, Andrew H Wei, Bruno Paiva, et al.
Blood|April 30, 2011
Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemiaMélanie Bonnet, Marie Loosveld, Bertrand Montpellier, et al.
The Lancet. Haematology|July 22, 2024
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, et al.
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
In Vivo (Athens, Greece)|June 23, 2022
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AMLDaniel H Albert, Neal C Goodwin, Angela M Davies, et al.
Lancet (London, England)|June 13, 2023
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trialUwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, et al.
Pageof 10